Position in PVLA
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$44,678,455
+$27,900,565 QoQ
Shares Held
292,360
+117.2% QoQ
Ownership
2.03%
of shares outstanding
% of Portfolio
0.88%
of 13F equity value
Holder Rank
#13
of 197 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 42%
Shared 0%
None 58%
Common Shares in PVLA Over Time
Shares Held
Position Value (USD)
Derivatives in PVLA
reported options exposure · as of Jun 30, 2026CallValue
$6,112,800
CallShares
40,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026ORBIMED ADVISORS LLC holds $3,639,640,835 across 90 Biotechnology names. PVLA ranks #24 (1.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EWTX |
Edgewise Therapeutics, Inc.
|
15,518,492 | $630,516,329 | |
| 2 | ELVN |
Enliven Therapeutics, Inc.
|
6,776,632 | $343,914,074 | |
| 3 | MBX |
MBX Biosciences, Inc.
|
3,428,736 | $189,266,227 | |
| 4 | GPCR |
Structure Therapeutics Inc.
|
2,209,400 | $118,578,498 | |
| 5 | SION |
Sionna Therapeutics, Inc.
|
2,555,877 | $112,433,029 | |
| 6 | CRVS |
Corvus Pharmaceuticals, Inc.
|
7,165,006 | $107,045,189 | |
| 7 | AVBP |
ArriVent BioPharma, Inc.
|
3,027,328 | $105,169,374 | |
| 8 | ARGX |
Argenx SE
|
92,880 | $86,171,277 |
All Filings in PVLA
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6,112,800 | 40,000 | Call | Defined | 2026-08-14 | |
| 2026-06-30 | $44,678,455 | 292,360 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $6,232,500 | 50,000 | Call | Defined | 2026-05-15 | |
| 2026-03-31 | $16,777,890 | 134,600 | Shares | Defined | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||